NASDAQ:BCAB BioAtla (BCAB) Stock Price, News & Analysis $1.36 +0.03 (+1.95%) As of 10/21/2026 03:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About BioAtla Stock (NASDAQ:BCAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioAtla alerts:Sign Up Key Stats Today's Range$1.34▼$1.5050-Day Range$1.08▼$3.4552-Week Range$1.07▼$71.50Volume3,617 shsAverage Volume51,848 shsMarket Capitalization$2.26 millionP/E RatioN/ADividend YieldN/APrice Target$200.00Consensus RatingHold Company Overview BioAtla, Inc. was a biotechnology company focused on developing antibody-based cancer therapies. The company’s research centered on its Conditionally Active Biologics (CAB) platform, which was designed to create therapeutic antibodies that are preferentially activated in the tumor microenvironment while remaining less active in healthy tissue. BioAtla’s development pipeline included antibody-drug conjugates and other immuno-oncology candidates. Its leading programs included mecbotamab vedotin, also known as BA3011, an antibody-drug conjugate targeting AXL, and ozuriftamab vedotin, or BA3021, an antibody-drug conjugate directed at ROR2. The company evaluated these candidates in clinical studies for solid tumors and other cancers. Founded in 2007 and headquartered in San Diego, California, BioAtla advanced its programs through clinical development and collaborations intended to support the development of targeted cancer medicines. The company later reduced operations and pursued strategic alternatives after encountering clinical and financial challenges. Public disclosures indicated that BioAtla ultimately wound down its business, so its historical pipeline and platform provide the primary basis for describing the company.AI Generated. May Contain Errors. Read More BioAtla Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreBCAB MarketRank™: 1.14875701684 of 5 starsBioAtla scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingBioAtla has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialBioAtla has a consensus price target of $200.00, representing about 14,649.3% upside from its current price of $1.36.Amount of Analyst CoverageBioAtla has only been the subject of 1 research reports in the past 90 days.Read more about BioAtla's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioAtla's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BCAB. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 2 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have not sold or bought any company stock.Percentage Held by Insiders9.34% of the stock of BioAtla is held by insiders.Percentage Held by Institutions77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioAtla's insider trading history. Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCAB Stock News HeadlinesContrasting BioAtla (NASDAQ:BCAB) and Bicycle Therapeutics (NASDAQ:BCYC)October 12, 2026 | americanbankingnews.comBioAtla Announces $40 Million Oncology SPV Investment DealMay 29, 2026 | theglobeandmail.comLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time. | Profits Run (Ad)BioAtla Announces Share ConsolidationMarch 31, 2026 | globenewswire.comBioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsMarch 31, 2026 | globenewswire.comBioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder ValueMarch 2, 2026 | quiverquant.comQBioAtla Announces Formal Process to Evaluate Strategic Options to Monetize AssetsMarch 2, 2026 | globenewswire.comBioAtla Faces Nasdaq Trading Suspension and Potential DelistingFebruary 6, 2026 | tipranks.comSee More Headlines BCAB Stock Analysis - Frequently Asked Questions How have BCAB shares performed this year? BioAtla's stock was trading at $28.3850 on January 1st, 2026. Since then, BCAB stock has decreased by 95.2% and is now trading at $1.3560. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) released its quarterly earnings results on Thursday, August, 13th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of ($8.50) by $8.64. The business earned $6.50 million during the quarter, compared to analyst estimates of $6.50 million. When did BioAtla's stock split? BioAtla's stock reverse split on Monday, April 6th 2026.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, April 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did BioAtla IPO? BioAtla (BCAB) raised $168 million in an IPO on Wednesday, December 16th 2020. The company issued 10,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioAtla own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioAtla investors own include Rigetti Computing (RGTI), Palantir Technologies (PLTR), D-Wave Quantum (QBTS), Archer Aviation (ACHR), NIO (NIO), Aurora Cannabis (ACB) and Coinbase Global (COIN). Company Calendar Last Earnings8/13/2026Today10/22/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BCAB's financial health is in the Red zone, according to TradeSmith. BCAB has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCAB CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees60Year Founded2007Price Target and Rating Average Price Target for BioAtla$200.00 High Price Target$200.00 Low Price Target$200.00 Potential Upside/Downside+14,649.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($25.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.61 million Net MarginsN/A Pretax Margin-370.05% Return on EquityN/A Return on Assets-289.67% Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio0.20 Sales & Book Value Annual Sales$8.50 million Price / Sales0.27 Cash FlowN/A Price / Cash FlowN/A Book Value($28.51) per share Price / Book-0.05Miscellaneous Outstanding Shares1,666,000Free Float1,510,000Market Cap$2.26 million OptionableNo Data Beta0.64 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:BCAB) was last updated on 10/21/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | Sponsored80 Days Until the Pentagon Restricts Chinese Rare EarthsChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
